Rocket Lab Analysts Trim Targets but Keep the Faith as Electron Nears Its 100th Launch

Rocket Lab's stock has drawn a wave of price-target revisions from Wall Street this week, yet not a single analyst has walked away from the bull case. Instead, the adjustments reveal a Street that is recalibrating its arithmetic while leaving its conviction intact — a distinction worth noting as the company prepares to mark a milestone in its launch history.

Needham cut its target to $100 from $120 on Wednesday while reaffirming its buy rating, according to media reports. A day earlier, Roth MKM had trimmed its own target to $80 from $110, also keeping a buy recommendation. The gap between the two — $20 — underscores how differently the houses are sizing up the same set of numbers. Two further research firms lowered their targets on Tuesday while maintaining overweight ratings, with new objectives reported between $82 and $111. Across all four actions, the rating itself stayed put.

The stock slipped 2.8% on the day before the Needham move, though no link between that session's decline and the analyst decision has been established.

A Backlog That Demands Delivery

What sits behind these revisions is a business growing fast but still burning cash. Rocket Lab reported third-quarter 2026 revenue of $268 million, up 73% year over year, alongside a net loss of $79.7 million. Its order book reached a record of roughly $3.6 billion — $3.57 billion on the company's Monday disclosure — giving management a deep pipeline to draw on. For the fourth quarter, the company has guided to revenue of $270 million to $290 million.

Should investors sell immediately? Or is it worth buying Rocket Lab?

Berenberg, for its part, is looking past the headline numbers to the demand side. The firm raised its target to $85 from $83 on Wednesday and kept its buy rating, arguing that the market underestimates both launch demand and pricing. Launch bookings are running at roughly seven times last year's pace, according to the analyst, and Neutron missions are already contracted into the 2030s. The stock was down 2.2% on the day.

That thesis rests on a simple proposition: a full manifest only matters if it converts into revenue at healthy margins. Rocket Lab disclosed a base launch price of $70 million for several Neutron missions, with 16 missions in the booked backlog. Higher prices could strengthen the economics — provided execution costs don't swallow the extra income.

The Margin Test

The near-term scorecard is already set. Management expects a GAAP gross margin of 34%–36% in the fourth quarter, a range that would lend substance to the optimistic case if hit. The counterweight is an anticipated adjusted EBITDA loss of $14 million to $20 million for the same period — a reminder that robust demand and a loss-making operation can coexist.

Morgan Stanley offered its own version of the same cautious optimism on Tuesday, reiterating an overweight rating while shaving its target to $103 from $105. The pattern across the Street is consistent: enthusiasm for the order book, tempered by the wait for evidence that bookings translate into a healthier bottom line.

Rocket Lab at a turning point? This analysis reveals what investors need to know now.

A Milestone on the Pad

Operationally, Rocket Lab has set Nov. 14 for the 100th launch of its Electron rocket. The mission is slated to lift an Earth-observation satellite for Japanese firm iQPS from Mahia, New Zealand. The company has announced the anniversary flight; it has not yet flown.

Further out, the first Neutron launch is targeted for no earlier than 2027. Until then, the bull case will be judged less on contract signings than on whether Rocket Lab can turn its $3.57 billion backlog into profitable flights — and whether the margin trajectory finally bends in the right direction.

Ad

Rocket Lab Stock: New Analysis - 13 November

Fresh Rocket Lab information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Rocket Lab analysis...